## Oxford PharmaGenesis Sustainability Strategy

## A note from our CEO

At Oxford PharmaGenesis, we build positive environmental, social and governance (ESG) practices into our operations, and are currently establishing a Board-backed global strategy for a sustainable future. We have committed to submit targets for validation by the Science Based Targets initiative (SBTi) before the end of 2023 and are putting in place an environmental management system (EMS) to monitor progress and drive continuous improvement in our environmental credentials.



Chris Winchester CEO. Oxford PharmaGenesis

We are one of more than 100 000 companies, across 175 countries and more than 200 industries that has submitted evidence to the ratings platform EcoVadis. Our silver medal, awarded in February 2023, indicates that we are in the highest-performing 25% of companies assessed.







At a local level, we have implemented practical schemes where possible, for example, using renewable energy, recycling, and cycle to work and electric vehicle benefits for employees. We also encourage employees to support local wildlife initiatives. In April 2023, we were delighted to welcome PharmaGenesis bees to one of our Oxford sites.

Sustainable



In early 2023, we published peer-reviewed research conducted in collaboration with the University of Oxford, revealing the climate change targets of the 20 leading global pharmaceutical companies and how they are reporting on and reducing their greenhouse gas emissions.1



Medicines **Partnership** 

We also collaborate with the **Sustainable Medicines** Partnership. Together we aim to reduce waste of medicines and waste from medicines, to make healthcare more equitable and sustainable.

**66** As a 500-strong HealthScience communications consultancy serving the pharmaceutical industry, we wanted to help understanding of the commitments that companies are making and the actions they need from suppliers like us to meet their goals.

Chris Winchester, CEO, Oxford PharmaGenesis

